Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
14.97
-1.98 (-11.68%)
Jan 29, 2026, 4:00 PM EST - Market closed
Palatin Technologies Employees
Palatin Technologies had 29 employees as of June 30, 2025. The number of employees decreased by 1 or -3.33% compared to the previous year.
Employees
29
Change (1Y)
-1
Growth (1Y)
-3.33%
Revenue / Employee
$305,088
Profits / Employee
-$165,730
Market Cap
27.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 29 | -1 | -3.33% |
| Jun 30, 2024 | 30 | -4 | -11.76% |
| Jun 30, 2023 | 34 | 1 | 3.03% |
| Jun 30, 2022 | 33 | 7 | 26.92% |
| Jun 30, 2021 | 26 | 6 | 30.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Boundless Bio | 64 |
| Senti Biosciences | 34 |
| Daré Bioscience | 23 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Rallybio | 15 |
| Serina Therapeutics | 13 |
PTN News
- 2 months ago - Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PRNewsWire
- 3 months ago - Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity - PRNewsWire
- 3 months ago - Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering - PRNewsWire
- 4 months ago - Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim - PRNewsWire
- 5 months ago - Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - GlobeNewsWire
- 6 months ago - Palatin Announces 1-for-50 Reverse Stock Split - PRNewsWire